References
1.
Öberg KE: Carcinoid and flushing syndromes; in Doherty GM, Skogseid B (eds): Surgical Endocrinology. Philadelphia, Lippincott Williams & Wilkins, 2001, chapt 28, pp 405–412.
2.
Ahlman H, Wängberg B, Nilsson O, Grimelius L, Granérus G, Modling IM, Stenqvist O, Scherstén T: Aspects on diagnosis and treatment of the foregut carcinoid syndrome. Scand J Gastroenterol 1992;27:459–471.
3.
Kölby L, Wängberg B, Ahlman H, Jansson S, Forssell-Aronsson E, Erickson JD, Nilsson O: Gastric carcinoid with histamine production, histamine transporter and expression of somatostatin receptors. Digestion 1998;59:160–166.
4.
Kölby L, Nilsson O, Ahlman H: Gastroduodenal endocrine tumours. Scand J Surg 2004;93:317–323.
5.
Roberts LJ 2nd, Marney SR Jr, Oates JA: Blockade of the flush associated with metastatic gastric carcinoid by combined H1 and H2 receptor antagonists: evidence for an important role of H2 receptors in human vasculature. N Engl J Med 1979;300:236–238.
6.
Vaughan DJA, Brunner MD: Anesthesia for patients with carcinoid syndrome. Int Anesthesiol Clin 1997;35:129–142.
7.
Graham GW, Unger BP, Coursin DB: Perioperative management of selected endocrine disorders. Int Anesthesiol Clin 2000;38:31–67.
8.
Lundin L, Hansson HE, Landelius J, Öberg K: Surgical treatment of carcinoid heart disease. J Thorac Cardiovasc Surg 1990;100:552–561.
9.
Pellikka PA, Tajik AJ, Khandheria BK, Seward JB, Callahan JA, Pitot HC, Kvols LK: Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. Circulation 1993;87:1188–1196.
10.
Westberg G, Wängberg B, Ahlman H, Bergh CH, Beckman-Suurküla M, Caidahl K: Prediction of prognosis by echocardiography in patients with midgut carcinoid syndrome. Br J Surg 2001;88:865–872.
11.
Milward MJ, Hung J, Blake MP, Gibson P, Byrne MJ: Left heart involvement with cardiac shunt complicating carcinoid heart disease. Aust NZ J Med 1989;19:716–717.
12.
Connolly HM, Schaff HV, Mullany CJ, Rubin J, Abel MD, Pellika PA: Surgical management of left-sided carcinoid heart disease. Circulation 2001;104:136–140.
13.
Weingarten TN, Abel MD, Connolly HM, Schroeder DR, Schaff HV: Intraoperative management of patients with carcinoid heart disease having valvular surgery: a review of 100 consecutive cases. Anesth Analg 2007;105:1192–1199.
14.
Sarmiento JM, Que FG: Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin N Am 2003;12:231–242.
15.
Botero M, Fuchs R, Paulus DA: Carcinoid heart disease: a case report and literature review. J Clin Anesth 2002;14:57–63.
16.
Janssen M, Salm EF, Breburda CS, van Woerkens LJ, de Herder WW, v/d Zwaan C, Roelandt JR: Carcinoid crisis during transesophageal echocardiography. Intensive Care Med 2000;26:254.
17.
Farling PA, Durairaju A: Remifentanil and anaesthesia for carcinoid syndrome. Br J Anaesth 2004;92:893–895.
18.
Hodul P, Malafa M, Choi J, Kvols L: The role of cytoreductive hepatic surgery as an adjunct to the management of metastatic neuroendocrine carcinomas. Cancer Control 2006;13:61–71.
19.
Que FG, Sarmiento JM, Nagorney DM: Hepatic surgery for metastatic gastrointestinal endocrine tumors. Adv Exp Med Biol 2006;574:43–56.
20.
Kinney MAO, Warner ME, Nagorney DM, Rubin J, Schroeder DR, Maxson PM, Warner MA: Perianaesthetic risks and outcomes of abdominal surgery for metastatic carcinoid tumours. Br J Anaesth 2001;87:447–452.
21.
Ahlman H, Åhlund L, Dahlström A, Martner J, Stenqvist O, Tylén U: SMS 201-995 and provocation tests in preparation of patients with carcinoids for surgery or hepatic arterial embolization. Anesth Analg 1988;67:1142–1148.
22.
Alghamdi AA, Jawas AM, Hart RS: Use of octreotide for the prevention of pancreatic fistula after elective pancreatic surgery: a systematic review and meta-analysis. Can J Surg 2007;50:459–466.
23.
Cisco RM, Norton JA: Surgery for gastrinoma. Adv Surg 2007;41:165–176.
24.
Ruzniewski P, Ramdani A, Cadiot G, Mignon M, Bonfils S: Long-term treatment with octreotide in patients with the Zollinger-Ellison syndrome. Eur J Clin Invest 1993;23:296–301.
25.
Fraker DL, Norton JA, Zahid AS, Maton PN, Gardner JD, Jensen RT: A prospective study of perioperative and postoperative control of acid hypersecretion in patients with Zollinger-Ellison syndrome undergoing gastrinoma resection. Surgery 1988;104:1054–1063.
26.
Grant CS: Insulinoma. Best Pract Res Clin Gastroenterol 2005;19:783–798.
27.
Doherty GM: Rare endocrine tumours of the gastrointestinal tract. Best Pract Res Clin Gastroenterol 2005;19:807–817.
© 2008 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the...
© 2008 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
